Antex Receives Patent on Vaccine to Prevent Ear Infections

Important Bacterial Protein Discovered Using Proteomics



Apr 26, 2001, 01:00 ET from Antex Biologics Inc.

    GAITHERSBURG, Md., April 26 /PRNewswire/ -- Antex Biologics Inc.
 (Amex:   ANX) today announced that it has been issued a patent on a Moraxella
 catarrhalis protein, which could prove useful as a vaccine to prevent middle
 ear infections (otitis media) in infants and children, and respiratory tract
 disease in the elderly. Antex has licensed the use of this patent to
 GlaxoSmithKline, which is responsible for the further preclinical and clinical
 development of this protein as a vaccine. Additionally, this invention has
 diagnostic applications.
     "We are very excited to have received this patent on the Moraxella
 catarrhalis protein," commented Stephen Keith, MD, MSPH, President, Antex
 Biologics. "Not only does this patent strengthen the Company's intellectual
 property portfolio, it increases the evidence of the robustness of Antex's
 vaccine and antibiotic discovery capabilities. We look forward to the
 continued development and future commercialization of this vaccine by
 GlaxoSmithKline."
     Moraxella catarrhalis is an important bacterial cause of respiratory tract
 disease, particularly otitis media, sinusitis, and pneumonia. This organism is
 responsible for up to 20 percent of episodes of bacterial otitis media in
 infants and young children. An estimated 5 million episodes of otitis media
 occur each year in the U.S. among infants and young children, at a cost of $3
 billion. Moraxella can also cause sinusitis and pneumonia in infants, children
 and adults, which may lead to life-threatening illness.
     AntexBiologics, together with its wholly owned subsidiary, AntexPharma, is
 a biopharmaceutical company committed to developing and marketing new products
 to prevent and treat infections and related diseases. The Company has three
 vaccine products in clinical development and has strategic alliances with
 GlaxoSmithKline, Aventis Pasteur, and the U.S. Department of Defense.
 
     Statements contained herein that relate to future events or results are
 forward-looking statements. Without limiting the foregoing, the words "may,"
 "will," "should," "intends," "estimates," "predicts," "potential," "continue,"
 "believes," "anticipates," "plans," "expects," the negative of these terms or
 other comparable terminology are intended to identify forward-looking
 statements. These statements are only predictions. A number of factors could
 cause actual results to differ materially from those indicated by forward-
 looking statements. In evaluating forward-looking statements, you should
 consider: (i) the Company's ability to fund its future operations; (ii) the
 Company's ability to successfully complete product research and development,
 including preclinical and clinical studies and commercialization; (iii) the
 Company's ability to obtain required governmental approvals; (iv) the
 Company's ability to attract and/or maintain manufacturing, sales,
 distribution and marketing partners; and (v) the Company's ability to develop
 and commercialize its products before its competitors.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33551791
 
 

SOURCE Antex Biologics Inc.
    GAITHERSBURG, Md., April 26 /PRNewswire/ -- Antex Biologics Inc.
 (Amex:   ANX) today announced that it has been issued a patent on a Moraxella
 catarrhalis protein, which could prove useful as a vaccine to prevent middle
 ear infections (otitis media) in infants and children, and respiratory tract
 disease in the elderly. Antex has licensed the use of this patent to
 GlaxoSmithKline, which is responsible for the further preclinical and clinical
 development of this protein as a vaccine. Additionally, this invention has
 diagnostic applications.
     "We are very excited to have received this patent on the Moraxella
 catarrhalis protein," commented Stephen Keith, MD, MSPH, President, Antex
 Biologics. "Not only does this patent strengthen the Company's intellectual
 property portfolio, it increases the evidence of the robustness of Antex's
 vaccine and antibiotic discovery capabilities. We look forward to the
 continued development and future commercialization of this vaccine by
 GlaxoSmithKline."
     Moraxella catarrhalis is an important bacterial cause of respiratory tract
 disease, particularly otitis media, sinusitis, and pneumonia. This organism is
 responsible for up to 20 percent of episodes of bacterial otitis media in
 infants and young children. An estimated 5 million episodes of otitis media
 occur each year in the U.S. among infants and young children, at a cost of $3
 billion. Moraxella can also cause sinusitis and pneumonia in infants, children
 and adults, which may lead to life-threatening illness.
     AntexBiologics, together with its wholly owned subsidiary, AntexPharma, is
 a biopharmaceutical company committed to developing and marketing new products
 to prevent and treat infections and related diseases. The Company has three
 vaccine products in clinical development and has strategic alliances with
 GlaxoSmithKline, Aventis Pasteur, and the U.S. Department of Defense.
 
     Statements contained herein that relate to future events or results are
 forward-looking statements. Without limiting the foregoing, the words "may,"
 "will," "should," "intends," "estimates," "predicts," "potential," "continue,"
 "believes," "anticipates," "plans," "expects," the negative of these terms or
 other comparable terminology are intended to identify forward-looking
 statements. These statements are only predictions. A number of factors could
 cause actual results to differ materially from those indicated by forward-
 looking statements. In evaluating forward-looking statements, you should
 consider: (i) the Company's ability to fund its future operations; (ii) the
 Company's ability to successfully complete product research and development,
 including preclinical and clinical studies and commercialization; (iii) the
 Company's ability to obtain required governmental approvals; (iv) the
 Company's ability to attract and/or maintain manufacturing, sales,
 distribution and marketing partners; and (v) the Company's ability to develop
 and commercialize its products before its competitors.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X33551791
 
 SOURCE  Antex Biologics Inc.